08:05 AM EST, 12/16/2024 (MT Newswires) -- Soligenix ( SNGX ) said Monday it has begun patient enrollment for its phase 3 study of its experimental therapy, HyBryte, to treat cutaneous T-cell lymphoma or CTCL.
The company said the study builds on previous phase 3 results and additional supportive research.